2008
The Feasibility of Adjuvant Carboplatin and Docetaxel in Patients with Curatively Resected Non-small Cell Lung Cancer
Stinchcombe TE, Harper HD, Hensing TA, Moore DT, Crane JM, Atkins JN, Willard EM, Detterbeck FC, Socinski MA. The Feasibility of Adjuvant Carboplatin and Docetaxel in Patients with Curatively Resected Non-small Cell Lung Cancer. Journal Of Thoracic Oncology 2008, 3: 145-151. PMID: 18303435, DOI: 10.1097/jto.0b013e318160c5f1.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCarcinoma, Non-Small-Cell LungChemotherapy, AdjuvantDocetaxelDrug-Related Side Effects and Adverse ReactionsFeasibility StudiesFemaleHumansLung NeoplasmsMaleMiddle AgedPatient ComplianceSurvival AnalysisTaxoidsConceptsNon-small cell lung cancerCell lung cancerAdjuvant therapySupportive therapyChemotherapy complianceLung cancerAdequate exposureResected non-small cell lung cancerAdjuvant cisplatin-based chemotherapyMulticenter phase II trialMedian age 65 yearsCycles of therapyPrimary end pointAcceptable toxicity profileBetter functional statusPhase II trialCisplatin-based chemotherapyMajority of patientsSquamous cell carcinomaAge 65 yearsAdjuvant carboplatinCommon histologyII trialIntercurrent illnessActive therapyNeoadjuvant Chemotherapy with Gemcitabine-Containing Regimens in Patients with Early-Stage Non-small Cell Lung Cancer
Detterbeck FC, Socinski MA, Gralla RJ, Edelman MJ, Jahan TM, Loesch DM, Limentani SA, Govindan R, Zaman MB, Ye Z, Monberg MJ, Obasaju CK. Neoadjuvant Chemotherapy with Gemcitabine-Containing Regimens in Patients with Early-Stage Non-small Cell Lung Cancer. Journal Of Thoracic Oncology 2008, 3: 37-45. PMID: 18166839, DOI: 10.1097/jto.0b013e31815e5d9a.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCarcinoma, Large CellCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellCisplatinDeoxycytidineDrug Administration ScheduleFeasibility StudiesFemaleFollow-Up StudiesGemcitabineHumansLung NeoplasmsMaleMiddle AgedNeoadjuvant TherapyNeoplasm StagingPaclitaxelSurvival AnalysisTime FactorsTreatment OutcomeConceptsEarly-stage non-small cell lung cancerNon-small cell lung cancerCell lung cancerGemcitabine 1000Day 1Neoadjuvant chemotherapyLung cancerResponse ratePathologic complete response rateRandomized phase II trialPhase III settingClinical response rateComplete response ratePerioperative mortality ratePrimary end pointComplete resection ratePhase II trialCarboplatin areaEligible patientsII trialPreoperative regimenResection rateSame regimenUnderwent surgeryMedian survival
2003
Gemcitabine-Based Combinations as Preoperative Therapy in Resectable Non–Small-Cell Lung Cancer
Socinski MA, Rivera MP, Detterbeck FC. Gemcitabine-Based Combinations as Preoperative Therapy in Resectable Non–Small-Cell Lung Cancer. Clinical Lung Cancer 2003, 4: s50-s55. PMID: 14720337, DOI: 10.3816/clc.2003.s.004.Peer-Reviewed Original ResearchGemcitabine-containing regimensPhase III trialsStage III NSCLCComplete surgical resectionPreoperative therapyIII trialsSurgical resectionInduction therapyLung cancerResectable non-small cell lung cancerNon-small cell lung cancerDominant recurrence patternGemcitabine-based combinationsSystemic micrometastatic diseaseCisplatin/gemcitabinePhase II trialMajority of patientsMinority of patientsCell lung cancerOverall response rateStandard of careAdjuvant chemotherapyAdvanced NSCLCII trialStage IB